Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-11

AUTHORS

Mathieu Rouanne, Mathieu Roumiguié, Nadine Houédé, Alexandra Masson-Lecomte, Pierre Colin, Géraldine Pignot, Stéphane Larré, Evanguelos Xylinas, Morgan Rouprêt, Yann Neuzillet

ABSTRACT

PURPOSE: Over the past 3 decades, no major treatment breakthrough has been reported for advanced bladder cancer. Recent Food and Drug Administration (FDA) approval of five immune checkpoint inhibitors in the management of advanced bladder cancer represent new therapeutic opportunities. This review examines the available data of the clinical trials leading to the approval of ICIs in the management of metastatic bladder cancer and the ongoing trials in advanced and localized settings. METHODS: A literature search was performed on PubMed and ClinicalTrials.gov combining the MeSH terms: 'urothelial carcinoma' OR 'bladder cancer', and 'immunotherapy' OR 'CTLA-4' OR 'PD-1' OR 'PD-L1' OR 'atezolizumab' OR 'nivolumab' OR 'ipilimumab' OR 'pembrolizumab' OR 'avelumab' OR 'durvalumab' OR 'tremelimumab'. Prospectives studies evaluating anti-PD(L)1 and anti-CTLA-4 monoclonal antibodies were included. RESULTS: Evidence-data related to early phase and phase III trials evaluating the 5 ICIs in the advanced urothelial carcinoma are detailed in this review. Anti-tumour activity of the 5 ICIs supporting the FDA approval in the second-line setting are reported. The activity of PD(L)1 inhibitors in the first-line setting in cisplatin-ineligible patients are also presented. Ongoing trials in earlier disease-states including non-muscle-invasive and muscle-invasive bladder cancer are discussed. CONCLUSIONS: Blocking the PD-1 negative immune receptor or its ligand, PD-L1, results in unprecedented rates of anti-tumour activity in patients with metastatic urothelial cancer. However, a large majority of patients do not respond to anti-PD(L)1 drugs monotherapy. Investigations exploring the potential value of predictive biomarkers, optimal combination and sequences are ongoing to improve such treatment strategies. More... »

PAGES

1727-1740

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00345-018-2332-5

DOI

http://dx.doi.org/10.1007/s00345-018-2332-5

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1104333388

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/29855698


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biomarkers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "CTLA-4 Antigen", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Carcinoma, Transitional Cell", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunologic Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunotherapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Molecular Targeted Therapy", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Programmed Cell Death 1 Receptor", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Assessment", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Survival Analysis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Treatment Outcome", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Urinary Bladder Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Institut Gustave Roussy", 
          "id": "https://www.grid.ac/institutes/grid.14925.3b", 
          "name": [
            "Department of Urology, H\u00f4pital Foch, Universit\u00e9 Versailles-Saint-Quentin-en-Yvelines, Universit\u00e9 Paris-Saclay, 40 Rue Worth, 92150, Suresnes, France", 
            "INSERM U1015, Gustave Roussy, Universit\u00e9 Paris-Saclay, Villejuif, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rouanne", 
        "givenName": "Mathieu", 
        "id": "sg:person.01217322503.47", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217322503.47"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, Institut Universitaire du Cancer, Oncopole, Toulouse, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roumigui\u00e9", 
        "givenName": "Mathieu", 
        "id": "sg:person.01307201702.74", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307201702.74"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Montpellier", 
          "id": "https://www.grid.ac/institutes/grid.121334.6", 
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Medical Oncology, CHU de N\u00eemes, Nimes, France", 
            "INSERM U1194, Montpellier Cancer Research Institute, Universit\u00e9 de Montpellier, Montpellier, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hou\u00e9d\u00e9", 
        "givenName": "Nadine", 
        "id": "sg:person.0605271475.46", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605271475.46"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, H\u00f4pital Saint-Louis, Universit\u00e9 Paris-Diderot, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Masson-Lecomte", 
        "givenName": "Alexandra", 
        "id": "sg:person.01226772576.78", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226772576.78"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, H\u00f4pital priv\u00e9 de la Louvi\u00e8re, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Colin", 
        "givenName": "Pierre", 
        "id": "sg:person.01353512175.13", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353512175.13"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Institute Paoli-Calmettes", 
          "id": "https://www.grid.ac/institutes/grid.418443.e", 
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, Institut Paoli-Calmettes, Marseille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pignot", 
        "givenName": "G\u00e9raldine", 
        "id": "sg:person.0756472605.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756472605.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire De Reims", 
          "id": "https://www.grid.ac/institutes/grid.139510.f", 
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, CHU de Reims, Reims, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Larr\u00e9", 
        "givenName": "St\u00e9phane", 
        "id": "sg:person.01130250616.37", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130250616.37"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Bichat-Claude-Bernard", 
          "id": "https://www.grid.ac/institutes/grid.411119.d", 
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, CHU Bichat, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Xylinas", 
        "givenName": "Evanguelos", 
        "id": "sg:person.01233162246.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233162246.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Piti\u00e9-Salp\u00eatri\u00e8re Hospital", 
          "id": "https://www.grid.ac/institutes/grid.411439.a", 
          "name": [
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France", 
            "Department of Urology, H\u00f4pital La Piti\u00e9-Salp\u00e9tri\u00e8re, AP-HP, GRC n\u00b05, ONCOTYPE-URO, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Roupr\u00eat", 
        "givenName": "Morgan", 
        "id": "sg:person.0740171455.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740171455.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "H\u00f4pital Foch", 
          "id": "https://www.grid.ac/institutes/grid.414106.6", 
          "name": [
            "Department of Urology, H\u00f4pital Foch, Universit\u00e9 Versailles-Saint-Quentin-en-Yvelines, Universit\u00e9 Paris-Saclay, 40 Rue Worth, 92150, Suresnes, France", 
            "Comit\u00e9 de Canc\u00e9rologie de l\u2019Association Fran\u00e7aise d\u2019Urologie (ccAFU), Bladder Cancer Group, Maison de l\u2019Urologie, Paris, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neuzillet", 
        "givenName": "Yann", 
        "id": "sg:person.0734372046.32", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734372046.32"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1158/2326-6066.cir-14-0069", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000298051"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature21349", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000326025", 
          "https://doi.org/10.1038/nature21349"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdu223", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003534006"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nature13904", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1003953337", 
          "https://doi.org/10.1038/nature13904"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1166-7087(16)30704-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1006386728"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/djs629", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007220641"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-10-0569", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008172147"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.5534", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008285055"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.coi.2010.02.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1008327899"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/fon.13.139", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009107940"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1126/science.1203486", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1010153811"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/cncr.22031", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013812122"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)00561-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017311610"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.critrevonc.2015.10.021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037372653"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.eururo.2016.06.020", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045458288"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(16)32455-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1046150233"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/imt.09.64", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047244065"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc3239", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047946992", 
          "https://doi.org/10.1038/nrc3239"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdw675", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1059394975"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-1741", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063225620"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30065-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074187151"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2001.19.10.2638", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1074814007"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2017.01.017", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083763156"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa1613683", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1083846671"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-3133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084230900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/1078-0432.ccr-16-3133", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1084230900"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdx225", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1085249345"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrclinonc.2017.101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1090892445", 
          "https://doi.org/10.1038/nrclinonc.2017.101"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1001/jamaoncol.2017.2411", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091234688"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30616-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1091930268"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.cell.2017.09.007", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1092131008"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1470-2045(17)30900-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099606489"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(17)33297-x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099711508"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.21037/tau.2017.09.18", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099828616"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-11", 
    "datePublishedReg": "2018-11-01", 
    "description": "PURPOSE: Over the past 3 decades, no major treatment breakthrough has been reported for advanced bladder cancer. Recent Food and Drug Administration (FDA) approval of five immune checkpoint inhibitors in the management of advanced bladder cancer represent new therapeutic opportunities. This review examines the available data of the clinical trials leading to the approval of ICIs in the management of metastatic bladder cancer and the ongoing trials in advanced and localized settings.\nMETHODS: A literature search was performed on PubMed and ClinicalTrials.gov combining the MeSH terms: 'urothelial carcinoma' OR 'bladder cancer', and 'immunotherapy' OR 'CTLA-4' OR 'PD-1' OR 'PD-L1' OR 'atezolizumab' OR 'nivolumab' OR 'ipilimumab' OR 'pembrolizumab' OR 'avelumab' OR 'durvalumab' OR 'tremelimumab'. Prospectives studies evaluating anti-PD(L)1 and anti-CTLA-4 monoclonal antibodies were included.\nRESULTS: Evidence-data related to early phase and phase III trials evaluating the 5 ICIs in the advanced urothelial carcinoma are detailed in this review. Anti-tumour activity of the 5 ICIs supporting the FDA approval in the second-line setting are reported. The activity of PD(L)1 inhibitors in the first-line setting in cisplatin-ineligible patients are also presented. Ongoing trials in earlier disease-states including non-muscle-invasive and muscle-invasive bladder cancer are discussed.\nCONCLUSIONS: Blocking the PD-1 negative immune receptor or its ligand, PD-L1, results in unprecedented rates of anti-tumour activity in patients with metastatic urothelial cancer. However, a large majority of patients do not respond to anti-PD(L)1 drugs monotherapy. Investigations exploring the potential value of predictive biomarkers, optimal combination and sequences are ongoing to improve such treatment strategies.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00345-018-2332-5", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094127", 
        "issn": [
          "0724-4983", 
          "1433-8726"
        ], 
        "name": "World Journal of Urology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "11", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "36"
      }
    ], 
    "name": "Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways", 
    "pagination": "1727-1740", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "c59c8def3d6c93be119624b01777c2d6a89d3f024fc46b3019123adaec4c3278"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "29855698"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8307716"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00345-018-2332-5"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1104333388"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00345-018-2332-5", 
      "https://app.dimensions.ai/details/publication/pub.1104333388"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T09:37", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000346_0000000346/records_99829_00000004.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00345-018-2332-5"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2332-5'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2332-5'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2332-5'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00345-018-2332-5'


 

This table displays all metadata directly associated to this object as RDF triples.

334 TRIPLES      21 PREDICATES      78 URIs      37 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00345-018-2332-5 schema:about N1c7b183be84745d0b46b337aab96db33
2 N247ccc7c91f24290bc26fa69d306d769
3 N289ba94aa424420f92f6e14ca5ee0e55
4 N37c925de72884b3a984b599c941ce3be
5 N534bbdd258c04a4f874729411ebe242e
6 N57b66f0b7cea4abda0db4d7f8ef384b9
7 N5c22f8995c3048ca855367e4a11c6b1e
8 N5ec1389d327f400db514c0f413c1c520
9 N68a4f150a7a549bdb713e6eeb046daaf
10 N76265054842243a38c4bdb4c7b48f0b1
11 N80d76d913c544357b1885f23df056669
12 Nac5ace4bf8824d08ab4e5aafe54ed94d
13 Naf025aa4d15343d093a58bac296c8535
14 Nbe68922ba32747c9bd5078336d612b24
15 Nd155f2d81b974da8aadea5541f40394f
16 Ne088b54d83cd42fab0b83d8af73a6110
17 anzsrc-for:11
18 anzsrc-for:1112
19 schema:author N97dce63fb36e4e5db38063774a5bd81a
20 schema:citation sg:pub.10.1038/nature13904
21 sg:pub.10.1038/nature21349
22 sg:pub.10.1038/nrc3239
23 sg:pub.10.1038/nrclinonc.2017.101
24 https://doi.org/10.1001/jamaoncol.2017.2411
25 https://doi.org/10.1002/cncr.22031
26 https://doi.org/10.1016/j.cell.2017.01.017
27 https://doi.org/10.1016/j.cell.2017.09.007
28 https://doi.org/10.1016/j.coi.2010.02.013
29 https://doi.org/10.1016/j.critrevonc.2015.10.021
30 https://doi.org/10.1016/j.eururo.2016.06.020
31 https://doi.org/10.1016/s0140-6736(16)00561-4
32 https://doi.org/10.1016/s0140-6736(16)32455-2
33 https://doi.org/10.1016/s0140-6736(17)33297-x
34 https://doi.org/10.1016/s1166-7087(16)30704-7
35 https://doi.org/10.1016/s1470-2045(17)30065-7
36 https://doi.org/10.1016/s1470-2045(17)30616-2
37 https://doi.org/10.1016/s1470-2045(17)30900-2
38 https://doi.org/10.1056/nejmoa1613683
39 https://doi.org/10.1093/annonc/mdu223
40 https://doi.org/10.1093/annonc/mdw675
41 https://doi.org/10.1093/annonc/mdx225
42 https://doi.org/10.1093/jnci/djs629
43 https://doi.org/10.1126/science.1203486
44 https://doi.org/10.1158/1078-0432.ccr-10-0569
45 https://doi.org/10.1158/1078-0432.ccr-16-1741
46 https://doi.org/10.1158/1078-0432.ccr-16-3133
47 https://doi.org/10.1158/2326-6066.cir-14-0069
48 https://doi.org/10.1200/jco.2001.19.10.2638
49 https://doi.org/10.1200/jco.2008.20.5534
50 https://doi.org/10.21037/tau.2017.09.18
51 https://doi.org/10.2217/fon.13.139
52 https://doi.org/10.2217/imt.09.64
53 schema:datePublished 2018-11
54 schema:datePublishedReg 2018-11-01
55 schema:description PURPOSE: Over the past 3 decades, no major treatment breakthrough has been reported for advanced bladder cancer. Recent Food and Drug Administration (FDA) approval of five immune checkpoint inhibitors in the management of advanced bladder cancer represent new therapeutic opportunities. This review examines the available data of the clinical trials leading to the approval of ICIs in the management of metastatic bladder cancer and the ongoing trials in advanced and localized settings. METHODS: A literature search was performed on PubMed and ClinicalTrials.gov combining the MeSH terms: 'urothelial carcinoma' OR 'bladder cancer', and 'immunotherapy' OR 'CTLA-4' OR 'PD-1' OR 'PD-L1' OR 'atezolizumab' OR 'nivolumab' OR 'ipilimumab' OR 'pembrolizumab' OR 'avelumab' OR 'durvalumab' OR 'tremelimumab'. Prospectives studies evaluating anti-PD(L)1 and anti-CTLA-4 monoclonal antibodies were included. RESULTS: Evidence-data related to early phase and phase III trials evaluating the 5 ICIs in the advanced urothelial carcinoma are detailed in this review. Anti-tumour activity of the 5 ICIs supporting the FDA approval in the second-line setting are reported. The activity of PD(L)1 inhibitors in the first-line setting in cisplatin-ineligible patients are also presented. Ongoing trials in earlier disease-states including non-muscle-invasive and muscle-invasive bladder cancer are discussed. CONCLUSIONS: Blocking the PD-1 negative immune receptor or its ligand, PD-L1, results in unprecedented rates of anti-tumour activity in patients with metastatic urothelial cancer. However, a large majority of patients do not respond to anti-PD(L)1 drugs monotherapy. Investigations exploring the potential value of predictive biomarkers, optimal combination and sequences are ongoing to improve such treatment strategies.
56 schema:genre research_article
57 schema:inLanguage en
58 schema:isAccessibleForFree false
59 schema:isPartOf N6acd662b727148b8ad9b1f47d3c35ddb
60 Nd991ac5f9e0149cca6970fe6f7ac697b
61 sg:journal.1094127
62 schema:name Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways
63 schema:pagination 1727-1740
64 schema:productId N232dfee31d004c26aac4ca278bf289ea
65 N59b00e2d966f45aea7931e9a800ce5ff
66 N5e7f49953a374bb8b8088994cde45da7
67 N6c3b656fc6a041faa35ab497d6e44ec5
68 Nb6e81063a9714bb69a7abe9ddd29e3b2
69 schema:sameAs https://app.dimensions.ai/details/publication/pub.1104333388
70 https://doi.org/10.1007/s00345-018-2332-5
71 schema:sdDatePublished 2019-04-11T09:37
72 schema:sdLicense https://scigraph.springernature.com/explorer/license/
73 schema:sdPublisher N2a546cd0fac44a7fac0a49f536d545d8
74 schema:url https://link.springer.com/10.1007%2Fs00345-018-2332-5
75 sgo:license sg:explorer/license/
76 sgo:sdDataset articles
77 rdf:type schema:ScholarlyArticle
78 N1c7b183be84745d0b46b337aab96db33 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
79 schema:name Female
80 rdf:type schema:DefinedTerm
81 N232dfee31d004c26aac4ca278bf289ea schema:name dimensions_id
82 schema:value pub.1104333388
83 rdf:type schema:PropertyValue
84 N247ccc7c91f24290bc26fa69d306d769 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
85 schema:name Prognosis
86 rdf:type schema:DefinedTerm
87 N26020b854aa94defa814c491969f65db rdf:first sg:person.01226772576.78
88 rdf:rest Nbf10e13f80e84ac59928f60b2d62b40f
89 N289ba94aa424420f92f6e14ca5ee0e55 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Disease-Free Survival
91 rdf:type schema:DefinedTerm
92 N2a546cd0fac44a7fac0a49f536d545d8 schema:name Springer Nature - SN SciGraph project
93 rdf:type schema:Organization
94 N37c925de72884b3a984b599c941ce3be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Molecular Targeted Therapy
96 rdf:type schema:DefinedTerm
97 N4503c90c24214a0bb8f92932bc48e049 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
98 Department of Urology, Hôpital Saint-Louis, Université Paris-Diderot, Paris, France
99 rdf:type schema:Organization
100 N4a39bf0f040f40ebaa57b93b69ccbc65 rdf:first sg:person.0740171455.76
101 rdf:rest N52f656914af34b979c69234f550f119f
102 N52f656914af34b979c69234f550f119f rdf:first sg:person.0734372046.32
103 rdf:rest rdf:nil
104 N534bbdd258c04a4f874729411ebe242e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
105 schema:name Male
106 rdf:type schema:DefinedTerm
107 N5541fc09ceef4e139a7a962b924b5810 rdf:first sg:person.01130250616.37
108 rdf:rest Nb542ffe7cbbf4a7ca0393ee34d4f8ed6
109 N57b66f0b7cea4abda0db4d7f8ef384b9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
110 schema:name Risk Assessment
111 rdf:type schema:DefinedTerm
112 N59b00e2d966f45aea7931e9a800ce5ff schema:name doi
113 schema:value 10.1007/s00345-018-2332-5
114 rdf:type schema:PropertyValue
115 N5c22f8995c3048ca855367e4a11c6b1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
116 schema:name Carcinoma, Transitional Cell
117 rdf:type schema:DefinedTerm
118 N5e7f49953a374bb8b8088994cde45da7 schema:name readcube_id
119 schema:value c59c8def3d6c93be119624b01777c2d6a89d3f024fc46b3019123adaec4c3278
120 rdf:type schema:PropertyValue
121 N5ec1389d327f400db514c0f413c1c520 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Treatment Outcome
123 rdf:type schema:DefinedTerm
124 N68a4f150a7a549bdb713e6eeb046daaf schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Immunotherapy
126 rdf:type schema:DefinedTerm
127 N6acd662b727148b8ad9b1f47d3c35ddb schema:volumeNumber 36
128 rdf:type schema:PublicationVolume
129 N6c3b656fc6a041faa35ab497d6e44ec5 schema:name nlm_unique_id
130 schema:value 8307716
131 rdf:type schema:PropertyValue
132 N6e6c099bd5af43e48b2fbba1ff175b3b rdf:first sg:person.01307201702.74
133 rdf:rest N8be2d2c7f7274f5eaed0715ee1edee9c
134 N76265054842243a38c4bdb4c7b48f0b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Survival Analysis
136 rdf:type schema:DefinedTerm
137 N787e6cbbe47543b89db501ba5a87fe65 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
138 Department of Urology, Institut Universitaire du Cancer, Oncopole, Toulouse, France
139 rdf:type schema:Organization
140 N80d76d913c544357b1885f23df056669 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
141 schema:name Urinary Bladder Neoplasms
142 rdf:type schema:DefinedTerm
143 N8be2d2c7f7274f5eaed0715ee1edee9c rdf:first sg:person.0605271475.46
144 rdf:rest N26020b854aa94defa814c491969f65db
145 N97dce63fb36e4e5db38063774a5bd81a rdf:first sg:person.01217322503.47
146 rdf:rest N6e6c099bd5af43e48b2fbba1ff175b3b
147 Nac5ace4bf8824d08ab4e5aafe54ed94d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
148 schema:name Programmed Cell Death 1 Receptor
149 rdf:type schema:DefinedTerm
150 Naf025aa4d15343d093a58bac296c8535 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
151 schema:name Humans
152 rdf:type schema:DefinedTerm
153 Nb542ffe7cbbf4a7ca0393ee34d4f8ed6 rdf:first sg:person.01233162246.75
154 rdf:rest N4a39bf0f040f40ebaa57b93b69ccbc65
155 Nb6e81063a9714bb69a7abe9ddd29e3b2 schema:name pubmed_id
156 schema:value 29855698
157 rdf:type schema:PropertyValue
158 Nbe68922ba32747c9bd5078336d612b24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Immunologic Factors
160 rdf:type schema:DefinedTerm
161 Nbf10e13f80e84ac59928f60b2d62b40f rdf:first sg:person.01353512175.13
162 rdf:rest Nc6f50c03347541e39ebb4f6e6c5e4c02
163 Nc6f50c03347541e39ebb4f6e6c5e4c02 rdf:first sg:person.0756472605.99
164 rdf:rest N5541fc09ceef4e139a7a962b924b5810
165 Ncd3733d4c25f44b39a6d24a1193b265c schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
166 Department of Urology, Hôpital privé de la Louvière, Lille, France
167 rdf:type schema:Organization
168 Nd155f2d81b974da8aadea5541f40394f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
169 schema:name CTLA-4 Antigen
170 rdf:type schema:DefinedTerm
171 Nd991ac5f9e0149cca6970fe6f7ac697b schema:issueNumber 11
172 rdf:type schema:PublicationIssue
173 Ne088b54d83cd42fab0b83d8af73a6110 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Biomarkers
175 rdf:type schema:DefinedTerm
176 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
177 schema:name Medical and Health Sciences
178 rdf:type schema:DefinedTerm
179 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
180 schema:name Oncology and Carcinogenesis
181 rdf:type schema:DefinedTerm
182 sg:journal.1094127 schema:issn 0724-4983
183 1433-8726
184 schema:name World Journal of Urology
185 rdf:type schema:Periodical
186 sg:person.01130250616.37 schema:affiliation https://www.grid.ac/institutes/grid.139510.f
187 schema:familyName Larré
188 schema:givenName Stéphane
189 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01130250616.37
190 rdf:type schema:Person
191 sg:person.01217322503.47 schema:affiliation https://www.grid.ac/institutes/grid.14925.3b
192 schema:familyName Rouanne
193 schema:givenName Mathieu
194 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01217322503.47
195 rdf:type schema:Person
196 sg:person.01226772576.78 schema:affiliation N4503c90c24214a0bb8f92932bc48e049
197 schema:familyName Masson-Lecomte
198 schema:givenName Alexandra
199 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226772576.78
200 rdf:type schema:Person
201 sg:person.01233162246.75 schema:affiliation https://www.grid.ac/institutes/grid.411119.d
202 schema:familyName Xylinas
203 schema:givenName Evanguelos
204 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01233162246.75
205 rdf:type schema:Person
206 sg:person.01307201702.74 schema:affiliation N787e6cbbe47543b89db501ba5a87fe65
207 schema:familyName Roumiguié
208 schema:givenName Mathieu
209 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01307201702.74
210 rdf:type schema:Person
211 sg:person.01353512175.13 schema:affiliation Ncd3733d4c25f44b39a6d24a1193b265c
212 schema:familyName Colin
213 schema:givenName Pierre
214 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01353512175.13
215 rdf:type schema:Person
216 sg:person.0605271475.46 schema:affiliation https://www.grid.ac/institutes/grid.121334.6
217 schema:familyName Houédé
218 schema:givenName Nadine
219 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605271475.46
220 rdf:type schema:Person
221 sg:person.0734372046.32 schema:affiliation https://www.grid.ac/institutes/grid.414106.6
222 schema:familyName Neuzillet
223 schema:givenName Yann
224 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0734372046.32
225 rdf:type schema:Person
226 sg:person.0740171455.76 schema:affiliation https://www.grid.ac/institutes/grid.411439.a
227 schema:familyName Rouprêt
228 schema:givenName Morgan
229 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0740171455.76
230 rdf:type schema:Person
231 sg:person.0756472605.99 schema:affiliation https://www.grid.ac/institutes/grid.418443.e
232 schema:familyName Pignot
233 schema:givenName Géraldine
234 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0756472605.99
235 rdf:type schema:Person
236 sg:pub.10.1038/nature13904 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003953337
237 https://doi.org/10.1038/nature13904
238 rdf:type schema:CreativeWork
239 sg:pub.10.1038/nature21349 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000326025
240 https://doi.org/10.1038/nature21349
241 rdf:type schema:CreativeWork
242 sg:pub.10.1038/nrc3239 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047946992
243 https://doi.org/10.1038/nrc3239
244 rdf:type schema:CreativeWork
245 sg:pub.10.1038/nrclinonc.2017.101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1090892445
246 https://doi.org/10.1038/nrclinonc.2017.101
247 rdf:type schema:CreativeWork
248 https://doi.org/10.1001/jamaoncol.2017.2411 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091234688
249 rdf:type schema:CreativeWork
250 https://doi.org/10.1002/cncr.22031 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013812122
251 rdf:type schema:CreativeWork
252 https://doi.org/10.1016/j.cell.2017.01.017 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083763156
253 rdf:type schema:CreativeWork
254 https://doi.org/10.1016/j.cell.2017.09.007 schema:sameAs https://app.dimensions.ai/details/publication/pub.1092131008
255 rdf:type schema:CreativeWork
256 https://doi.org/10.1016/j.coi.2010.02.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008327899
257 rdf:type schema:CreativeWork
258 https://doi.org/10.1016/j.critrevonc.2015.10.021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037372653
259 rdf:type schema:CreativeWork
260 https://doi.org/10.1016/j.eururo.2016.06.020 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045458288
261 rdf:type schema:CreativeWork
262 https://doi.org/10.1016/s0140-6736(16)00561-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017311610
263 rdf:type schema:CreativeWork
264 https://doi.org/10.1016/s0140-6736(16)32455-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1046150233
265 rdf:type schema:CreativeWork
266 https://doi.org/10.1016/s0140-6736(17)33297-x schema:sameAs https://app.dimensions.ai/details/publication/pub.1099711508
267 rdf:type schema:CreativeWork
268 https://doi.org/10.1016/s1166-7087(16)30704-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006386728
269 rdf:type schema:CreativeWork
270 https://doi.org/10.1016/s1470-2045(17)30065-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074187151
271 rdf:type schema:CreativeWork
272 https://doi.org/10.1016/s1470-2045(17)30616-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1091930268
273 rdf:type schema:CreativeWork
274 https://doi.org/10.1016/s1470-2045(17)30900-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099606489
275 rdf:type schema:CreativeWork
276 https://doi.org/10.1056/nejmoa1613683 schema:sameAs https://app.dimensions.ai/details/publication/pub.1083846671
277 rdf:type schema:CreativeWork
278 https://doi.org/10.1093/annonc/mdu223 schema:sameAs https://app.dimensions.ai/details/publication/pub.1003534006
279 rdf:type schema:CreativeWork
280 https://doi.org/10.1093/annonc/mdw675 schema:sameAs https://app.dimensions.ai/details/publication/pub.1059394975
281 rdf:type schema:CreativeWork
282 https://doi.org/10.1093/annonc/mdx225 schema:sameAs https://app.dimensions.ai/details/publication/pub.1085249345
283 rdf:type schema:CreativeWork
284 https://doi.org/10.1093/jnci/djs629 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007220641
285 rdf:type schema:CreativeWork
286 https://doi.org/10.1126/science.1203486 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010153811
287 rdf:type schema:CreativeWork
288 https://doi.org/10.1158/1078-0432.ccr-10-0569 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008172147
289 rdf:type schema:CreativeWork
290 https://doi.org/10.1158/1078-0432.ccr-16-1741 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063225620
291 rdf:type schema:CreativeWork
292 https://doi.org/10.1158/1078-0432.ccr-16-3133 schema:sameAs https://app.dimensions.ai/details/publication/pub.1084230900
293 rdf:type schema:CreativeWork
294 https://doi.org/10.1158/2326-6066.cir-14-0069 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000298051
295 rdf:type schema:CreativeWork
296 https://doi.org/10.1200/jco.2001.19.10.2638 schema:sameAs https://app.dimensions.ai/details/publication/pub.1074814007
297 rdf:type schema:CreativeWork
298 https://doi.org/10.1200/jco.2008.20.5534 schema:sameAs https://app.dimensions.ai/details/publication/pub.1008285055
299 rdf:type schema:CreativeWork
300 https://doi.org/10.21037/tau.2017.09.18 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099828616
301 rdf:type schema:CreativeWork
302 https://doi.org/10.2217/fon.13.139 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009107940
303 rdf:type schema:CreativeWork
304 https://doi.org/10.2217/imt.09.64 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047244065
305 rdf:type schema:CreativeWork
306 https://www.grid.ac/institutes/grid.121334.6 schema:alternateName University of Montpellier
307 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
308 Department of Medical Oncology, CHU de Nîmes, Nimes, France
309 INSERM U1194, Montpellier Cancer Research Institute, Université de Montpellier, Montpellier, France
310 rdf:type schema:Organization
311 https://www.grid.ac/institutes/grid.139510.f schema:alternateName Centre Hospitalier Universitaire De Reims
312 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
313 Department of Urology, CHU de Reims, Reims, France
314 rdf:type schema:Organization
315 https://www.grid.ac/institutes/grid.14925.3b schema:alternateName Institut Gustave Roussy
316 schema:name Department of Urology, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, 40 Rue Worth, 92150, Suresnes, France
317 INSERM U1015, Gustave Roussy, Université Paris-Saclay, Villejuif, France
318 rdf:type schema:Organization
319 https://www.grid.ac/institutes/grid.411119.d schema:alternateName Hôpital Bichat-Claude-Bernard
320 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
321 Department of Urology, CHU Bichat, Paris, France
322 rdf:type schema:Organization
323 https://www.grid.ac/institutes/grid.411439.a schema:alternateName Pitié-Salpêtrière Hospital
324 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
325 Department of Urology, Hôpital La Pitié-Salpétrière, AP-HP, GRC n°5, ONCOTYPE-URO, Paris, France
326 rdf:type schema:Organization
327 https://www.grid.ac/institutes/grid.414106.6 schema:alternateName Hôpital Foch
328 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
329 Department of Urology, Hôpital Foch, Université Versailles-Saint-Quentin-en-Yvelines, Université Paris-Saclay, 40 Rue Worth, 92150, Suresnes, France
330 rdf:type schema:Organization
331 https://www.grid.ac/institutes/grid.418443.e schema:alternateName Institute Paoli-Calmettes
332 schema:name Comité de Cancérologie de l’Association Française d’Urologie (ccAFU), Bladder Cancer Group, Maison de l’Urologie, Paris, France
333 Department of Urology, Institut Paoli-Calmettes, Marseille, France
334 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...